糖基化终产物对人肾小球系膜细胞半乳糖凝集素3基因表达影响.docVIP

糖基化终产物对人肾小球系膜细胞半乳糖凝集素3基因表达影响 　 作者：马婵娟，孙子林，金晖，杨涛，杨益宁 ［摘要］　　目的：研究糖基化终产物（AGEs）对人肾小球系膜细胞半乳糖凝集素3 (galectin3)表达的影响。方法：将培养的人肾小球系膜细胞(HRMC) 用不同浓度(50、100、200及400mg#12539;L-1)的AGEs干预24h或同一浓度(200mg#12539;L-1)的AGEs干预0、24、48及72h，以无血清培养基(DMEM)和相应浓度的牛血清白蛋白（BSA）为对照。用RTPCR检测细胞中半乳糖凝集素3的mRNA水平。结果：不同浓度AGEs组HRMC的半乳糖凝集素3 mRNA水平与对照组相比均有显著差异（P＜0.01），且随着AGEs浓度的增高，半乳糖凝集素3 mRNA水平也逐渐增高(P＜0.05)；AGEs干预HRMC 24、48、72h，半乳糖凝集素3 mRNA水平与对照组相比有显著差异（P＜0.05），且随着干预时间的延长，半乳糖凝集素3 mRNA水平也逐渐增高 (P＜0.01)。结论：AGEs以时间及剂量依赖的方式促进HRMC半乳糖凝集素3 mRNA的表达。 　　［关键词］糖基化终产物；人肾小球系膜细胞；糖尿病肾病；半乳糖凝集素3；基因表达 　　Abstract：Objective To study the effect of advanced glycation end products(AGEs) on the expression of galectin3 in cultured human renal mesangial cells(HRMC). Methods The AGEsBSA was prepared by incubating bovine serum albumin(BSA) with glucose.The cultured HRMC were intervened with the same concentration of BSA and AGEsBSA(50,100,200,400mg#12539; L-1) for 24h or 200 mg#12539; L-1 AGEsBSA for 0,24,48 or 72h respectively. The mRNA expression of galectin3 in HRMC were analyzed by RTPCR.Results Compared with that in cells incubated with DMEM and BSA,the level of galectin3 mRNA in cells incubated with 50,100 or 200,400mg#12539; L-1AGEsBSA respectively for 24h （P＜0.01）or with 200mg#12539; L-1AGEsBSA for 0,24,48 or 72h respectively（P＜0.05）increased significantly. Moreover, with the increased concentration of AGEsBSA（P＜0.05）or the expanded incubating time （P＜0.01）,the level of galectin3 mRNA increased. Conclusion The AGEsBSA can stimulate the expression of galectin3 in cultured HRMC in a concentration and timedependent manner. 　　Key words：advanced glycation end products; human renal mesangial cells; diabetic nephropathy; galectin3; gene expression 　　糖尿病肾病(diabetic nephropathy,DN)是1、2型糖尿病的慢性微血管并发症之一，是引起终末期肾病的最常见病因［1］。大量研究表明，糖基化终产物（advanced glycation end products,AGEs）在DN的发生发展过程中起了重要的作用［2］。AGEs致病的主要机制之一是其可以与细胞表面的AGEs受体相互作用，引发生物学效应。半乳糖凝集素3（galectin3）是AGEs的受体之一［3］，它(AGER3)与p60(AGER1)、 p90（AGER2）被认为作为一个分子复合体（AGE受体复合体）起作用。本实验应用体外制备的AGEs对人肾小